ArticleNature methods2017
Unexpected mutations after CRISPR-Cas9 editing in vivo.
RetractedAbstract read
In one paragraph
Article in Nature methods, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 150 papers.
0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed.
- Machine-learning in optimization of CRISPR technology.Machine learning. Health · 2026Review
- The Use of Deep Learning in RNA Therapeutic Development.ACS nano · 2026Review
- Mismatch prime editing gRNA increased efficiency and reduced indels.Nature communications · 2025Article
- Integration of RNAi and Small Molecule Library Screens to Identify Targets for Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision.Science advances · 2024Article
- Advancing cancer research through organoid technology.Journal of translational medicine · 2024Review
- Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases.Journal of clinical medicine · 2024Review
- Novel off-Targeting Events Identified after Genome Wide Analysis of CRISPR-Cas Edited Pigs.The CRISPR journal · 2024Article
- The role of zygotic genome activation in genetic-related reproductive medicine: Technological perspective, religious and bioethical concerns, challenges and benefits.Journal, genetic engineering & biotechnology · 2024Article
- An Update on the Application of CRISPR Technology in Clinical Practice.Molecular biotechnology · 2024Review
- In Silico Design of gRNA for CRISPR/Cas9-Mediated Gene Knockout.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Rare but diverse off-target and somatic mutations found in field and greenhouse grown trees expressing CRISPR/Cas9.Frontiers in bioengineering and biotechnology · 2024Article
- Revitalizing oral cancer research: Crispr-Cas9 technology the promise of genetic editing.Frontiers in oncology · 2024Review
- Transcriptional and proteomic analysis.GM crops & food · 2023Article
- CRISPR/Cas9: a powerful tool in colorectal cancer research.Journal of experimental & clinical cancer research : CR · 2023Review
- Challenges and new technologies in adoptive cell therapy.Journal of hematology & oncology · 2023Review
- Vector enabled CRISPR gene editing - A revolutionary strategy for targeting the diversity of brain pathologies.Coordination chemistry reviews · 2023Article
- Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies.Biomarker research · 2023Review
- From GWAS to signal validation: An approach for estimating genetic effects while preserving genomic context.bioRxiv : the preprint server for biology · 2023Article
- New advances in CRISPR/Cas-mediated precise gene-editing techniques.Disease models & mechanisms · 2023Review
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2018-03-30Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Objections by Author(s) · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2017-06-14Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions ·
- Expression of concern · 2017-07-25Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Objections by Author(s) · Upgrade/Update of Prior Notice(s) ·
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Kellie A SchaeferOmics Laboratory, Stanford University, Palo Alto, California, USA.
Wen-Hsuan WuJonas Children's Vision Care and Bernard &Shirlee Brown Glaucoma Laboratory, Departments of Ophthalmology, Pathology &Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Diana F ColganOmics Laboratory, Stanford University, Palo Alto, California, USA.
Stephen H TsangJonas Children's Vision Care and Bernard &Shirlee Brown Glaucoma Laboratory, Departments of Ophthalmology, Pathology &Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Alexander G BassukDepartment of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
Vinit B MahajanOmics Laboratory, Stanford University, Palo Alto, California, USA.
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MInstrumentation, Fabrication, and Design CoreP30EY019007 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Xin Zhang · 2010 to 2026
$12.9MToward mechanism- and gene-based therapies for retinal degenerationR01EY018213 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Stephen H Tsang · 2008 to 2026
$6.6MGene Silencing and Gene Editing in PhototransductionR01EY024698 · NEI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Stephen H Tsang · 2015 to 2026
$4.7MExploring Novel Epilepsy PathwaysR01NS098590 · NINDS · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G · 2016 to 2020
$2.8MStructure and Function of Calpain-5R01EY024665 · NEI · UNIVERSITY OF IOWA · PI MAHAJAN, VINIT B · 2015 to 2019
$1.9MMechanistic Studies on Regenerative Medicine Approaches to Childhood BlindnessR01EY026682 · NEI · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G, MAHAJAN, VINIT B · 2016 to 2019
$1.6MMechanism-based therapies for photoreceptor degenerationR01EY025225 · NEI · UNIVERSITY OF IOWA · PI MAHAJAN, VINIT B · 2015 to 2018
$1.3MMolecular Genetics of Dominant Neovascular Inflammatory VitreoretinopathyK08EY020530 · NEI · UNIVERSITY OF IOWA · PI MAHAJAN, VINIT B · 2011 to 2015
$1.1MEvaluating GWAS AMD Candidate Loci by Gene Editing in Human iPS CellsR21AG050437 · NIA · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G, MAHAJAN, VINIT B · 2015 to 2016
$431kCAPN5-PDGF Signaling in VitreoretinopathyF31EY026789 · NEI · UNIVERSITY OF IOWA · PI SCHAEFER, KELLIE A · 2016 to 2020
$149kNCI NIH HHS P30 CA013696NEI NIH HHS F31 EY026789NEI NIH HHS K08 EY020530NEI NIH HHS P30 EY019007NEI NIH HHS R01 EY018213NEI NIH HHS R01 EY024665NEI NIH HHS R01 EY024698NEI NIH HHS R01 EY025225NEI NIH HHS R01 EY026682NIA NIH HHS R21 AG050437NINDS NIH HHS R01 NS098590
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.